Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Seizert Capital Partners LLC

Seizert Capital Partners LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 54,304 shares of the biopharmaceutical company’s stock after buying an additional 8,529 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.7% of Seizert Capital Partners LLC’s holdings, making the stock its 26th biggest holding. Seizert Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $38,682,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of REGN. Oak Grove Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals by 48.0% during the fourth quarter. Oak Grove Capital LLC now owns 2,930 shares of the biopharmaceutical company’s stock valued at $2,087,000 after purchasing an additional 950 shares during the period. Victory Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 44.8% during the fourth quarter. Victory Capital Management Inc. now owns 139,891 shares of the biopharmaceutical company’s stock valued at $99,649,000 after acquiring an additional 43,282 shares during the period. Keybank National Association OH raised its holdings in Regeneron Pharmaceuticals by 6.5% during the fourth quarter. Keybank National Association OH now owns 1,239 shares of the biopharmaceutical company’s stock worth $883,000 after purchasing an additional 76 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its position in Regeneron Pharmaceuticals by 49.5% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 601 shares of the biopharmaceutical company’s stock worth $423,000 after purchasing an additional 199 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after purchasing an additional 22,538 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several research reports. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bernstein Bank cut their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Oppenheimer reduced their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $675.49 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market cap of $73.85 billion, a PE ratio of 17.65, a PEG ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The firm’s 50 day moving average price is $697.13 and its 200 day moving average price is $859.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.